Replimune Group, Inc. REPL
Updated: 9 Aug 2026
No signal published yet
We already track Replimune Group and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Replimune Group, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Replimune Group free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Replimune announced that the U.S. FDA granted accelerated approval for TUDRIQEV in combination with nivolumab for adults with advanced cutaneous melanoma who progressed on prior anti-PD-1 therapy. The approval was based on objective response rate and duration of response data from the IGNYTE trial. Continued approval may be contingent upon verification of clinical benefit in an ongoing confirmatory trial.
What Firelda Watch includes for Replimune Group, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Replimune Group, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Replimune Group free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more